References
1. Cloyd JM, Poultsides GA. The Landmark Series: Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021;28:1039-1049.
2. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589..
3. Aziz H, Howe JR, Pawlik TM. Surgery vs Observation for Patients With Small Pancreatic Neuroendocrine Tumors. JAMA Surg 2021;156:412-413. doi: 10.1001/jamasurg.2020.5640..
4. Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:1–33..
5. Hurtado-Pardo L, Cienfuegos JA, Antoñanzas J, et al. Incidental lesions of the pancreas. A clinicopathological study of 100 cases surgically treated. Revi Esp Enferm Digest 2020;112:85-89. doi: 10.17235/reed.2019.6118/2018
6. Barturen Á. Incidental pancreatic lesions - A diagnostic and management challenge. Rev Esp Enferm Digest; 2020;112:83–84.
7. Rotellar F, Pardo F, Montiel C, et al. Totally laparoscopic roux-en-Y duct-to-mucosa pancreaticojejunostomy after middle pancreatectomy: A consecutive nine-case series at a single institution. Ann Surg 2008;247:938-944.
8. Cienfuegos JA, Salguero J, Núñez-Córdoba JM, et al. Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience. Surg Endosc 2017;31:3847-3857.
9. Kimura W, Inoue T, Futakawa N, et al. Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein. Surgery 1996;120:885–890.
10. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.
11. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 2017;161:584–591..
12. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;142:761–8.
13. Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007;142:20–25.
14. Kloppel, G, Adsay NV, Couvelard A, et al. Pancreatic neuroendocrine neoplasms: introduction. In:WHO Classification of Tumours. Digestive System Tumours.WHO Classification of Tumours Editorial Board. 5th ed. Lyon (France) International Agency for Research on Cancer, 2019:343–346.
15. Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016;103:153–71.
16. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770–1786.
17. Wolters U, Wolf T, Stützer H, et al. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996;77:217–22..
18. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes care 2012;35 Suppl 1:S64-71.
19. Crippa S, Partelli S, Zamboni G, et al. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery 2014;155:145–153.
20. Birnbaum DJ, Gaujoux S, Cherif R, et al. Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. Surgery 2014;155:13–21.
21. Asbun HJ, Moekotte AL, Vissers FL, et al. The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Ann Surg 2020;271:1–14.
22. Kneuertz PJ, Pitt HA, Bilimoria KY, et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg. 2012;16:1727–35.
23. De Rooij T, Klompmaker S, Hilal MA, et al.. Laparoscopic pancreatic surgery for benign and malignant disease. Nat. Rev. Gastroenterol. Hepatol. 2016;13:227–238. https://pubmed.ncbi.nlm.nih.gov/26882881/..
24. Finkelstein P, Sharma R, Picado O, et al. Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection. J. Gastrointest. Surg. 2017;21:855–866.
25. Sadot E, Reidy-Lagunes DL, Tang LH, et al. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. Ann Surg Oncol 2016;23:1361–1370.
26. Kay BR, Witte DL. The impact of cancer biology, lead time bias, and length bias in the debate about cancer screening tests. J Insur Med 1991;23:102–4.
27. Kafadar K, Prorok PC. Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected. Stat Med 2009;28:2116–2146.
28. Assi HA, Mukherjee S, Kunz PL, et al. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. The oncologist 2020;25:e276–e283. http://www.ncbi.nlm.nih.gov/pubmed/32043766..
29. Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases. J Surg Oncol 2019;120:1071–1079.
30. Partelli S, Ramage JK, Massironi S, et al. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front Med 2020;7:1-8. http://www.ncbi.nlm.nih.gov/pubmed/33425946..